Share Price and Basic Stock Data
Last Updated: December 5, 2025, 7:59 pm
| PEG Ratio | 7.35 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Genpharmasec Ltd operates in the Trading & Distributors sector and has shown a notable increase in revenue over recent reporting periods. The company reported sales of ₹25.52 Cr in March 2023, which rose to ₹30.41 Cr in March 2024, and further to ₹33.57 Cr by March 2025. The trailing twelve months (TTM) sales stand at ₹40.56 Cr, indicating a consistent upward trend. Such growth can be attributed to improved operational strategies and perhaps an expanding market presence. However, the quarterly sales figures reveal fluctuations, with a peak of ₹14.01 Cr in March 2025, which then dipped to ₹12.04 Cr in June 2025. This volatility could raise concerns about demand stability and operational efficiency, suggesting that while the revenue trajectory is promising, it is not without its challenges.
Profitability and Efficiency Metrics
When examining profitability, Genpharmasec’s performance appears to be on a cautious path. The operating profit margin (OPM) was reported at a mere 1.02% for March 2023, and it slightly improved to 0.24% in March 2025. These figures suggest that while the company is generating sales, it is struggling to convert those sales into significant profits. The net profit for the latest fiscal year stood at ₹1.23 Cr, a recovery from a loss of ₹0.17 Cr in the previous year. However, the overall return on equity (ROE) is a modest 1.90%, indicating that shareholders may not see substantial returns on their investments. The cash conversion cycle (CCC) at 146.47 days also signals potential inefficiencies in managing working capital, as the company takes longer to convert its investments in inventory and receivables into cash.
Balance Sheet Strength and Financial Ratios
On the balance sheet front, Genpharmasec’s financial health presents a mixed picture. With total borrowings rising from ₹3.08 Cr in March 2023 to ₹11.01 Cr by September 2025, the company is increasing its leverage, which could be a double-edged sword. While this may support growth initiatives, it raises concerns about financial stability, especially given the interest coverage ratio (ICR) of 7.19x, which indicates that the company earns sufficient income to cover its interest obligations. The current ratio stands at a robust 2.78, suggesting that Genpharmasec is well-positioned to meet its short-term liabilities. However, the book value per share has remained relatively stagnant, slightly increasing from ₹1.17 to ₹1.18 over the period, which may indicate limited asset growth relative to equity capital.
Shareholding Pattern and Investor Confidence
Investor sentiment in Genpharmasec appears to be shifting, particularly regarding its shareholding composition. Promoter holdings have significantly decreased from 59.96% in March 2023 to 29.98% by March 2025, indicating a potential dilution of control that might concern some investors. Meanwhile, the public’s stake has increased to 70.02%, reflecting growing interest from retail investors. The number of shareholders surged from approximately 49,760 in March 2023 to over 1,09,000 by March 2025, suggesting that the stock is gaining traction among the public. This shift could be a sign of increasing confidence in the company’s prospects, but it also raises questions about the motivations behind the promoters’ reduced stake, which could be perceived as a lack of belief in the company’s future performance.
Outlook, Risks, and Final Insight
Looking ahead, Genpharmasec faces a landscape filled with both opportunities and risks. The company must navigate revenue volatility and profitability challenges while managing increased debt levels. Investors should be aware that while the rise in public shareholding indicates growing interest, the reduced promoter stake could signal underlying concerns. Additionally, the company’s ability to streamline its operations and enhance cash flow will be critical in mitigating risks associated with working capital management. As the company works to solidify its market position, maintaining a balance between growth initiatives and financial prudence will be essential. Investors might consider these factors carefully, weighing the potential for growth against the inherent risks of a fluctuating business environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genpharmasec Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Minal Industries Ltd | 64.3 Cr. | 3.35 | 5.59/3.20 | 42.9 | 2.78 | 0.00 % | 5.97 % | 2.83 % | 2.00 |
| Mitshi India Ltd | 13.0 Cr. | 14.7 | 18.6/13.0 | 3.09 | 0.00 % | 0.36 % | 0.37 % | 10.0 | |
| Modella Woollens Ltd | 5.94 Cr. | 65.3 | 74.8/52.5 | 4.95 | 0.00 % | % | % | 10.0 | |
| MRC Agrotech Ltd | 103 Cr. | 50.4 | 54.5/10.2 | 115 | 15.1 | 0.00 % | 5.89 % | 4.46 % | 10.0 |
| MRP Agro Ltd | 107 Cr. | 96.0 | 174/84.4 | 15.1 | 30.6 | 0.00 % | 39.2 % | 30.3 % | 10.0 |
| Industry Average | 11,033.45 Cr | 161.57 | 90.12 | 120.92 | 0.40% | 15.37% | 8.86% | 7.74 |
Quarterly Result
| Metric | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.22 | 7.86 | 6.38 | 10.20 | 5.20 | 6.03 | 8.48 | 14.01 | 12.04 |
| Expenses | 6.01 | 7.89 | 6.37 | 10.21 | 5.00 | 5.90 | 7.74 | 15.01 | 11.10 |
| Operating Profit | 0.21 | -0.03 | 0.01 | -0.01 | 0.20 | 0.13 | 0.74 | -1.00 | 0.94 |
| OPM % | 3.38% | -0.38% | 0.16% | -0.10% | 3.85% | 2.16% | 8.73% | -7.14% | 7.81% |
| Other Income | 0.06 | 0.15 | 0.14 | 0.31 | 0.57 | 0.75 | 0.81 | 0.94 | 0.69 |
| Interest | 0.06 | 0.07 | 0.00 | 0.16 | 0.10 | 0.07 | 0.16 | 0.11 | 0.12 |
| Depreciation | 0.01 | 0.00 | 0.12 | 0.03 | 0.16 | 0.30 | 0.10 | 0.26 | 0.27 |
| Profit before tax | 0.20 | 0.05 | 0.03 | 0.11 | 0.51 | 0.51 | 1.29 | -0.43 | 1.24 |
| Tax % | -420.00% | 80.00% | -100.00% | 345.45% | 35.29% | -39.22% | 39.53% | -37.21% | 2.42% |
| Net Profit | 1.05 | 0.01 | 0.06 | -0.27 | 0.33 | 0.70 | 0.78 | -0.27 | 1.22 |
| EPS in Rs | 0.02 | 0.00 | 0.00 | -0.00 | 0.01 | 0.01 | 0.01 | -0.00 | 0.02 |
Last Updated: August 19, 2025, 2:45 pm
Below is a detailed analysis of the quarterly data for Genpharmasec Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 12.04 Cr.. The value appears to be declining and may need further review. It has decreased from 14.01 Cr. (Mar 2025) to 12.04 Cr., marking a decrease of 1.97 Cr..
- For Expenses, as of Jun 2025, the value is 11.10 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 15.01 Cr. (Mar 2025) to 11.10 Cr., marking a decrease of 3.91 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.94 Cr.. The value appears strong and on an upward trend. It has increased from -1.00 Cr. (Mar 2025) to 0.94 Cr., marking an increase of 1.94 Cr..
- For OPM %, as of Jun 2025, the value is 7.81%. The value appears strong and on an upward trend. It has increased from -7.14% (Mar 2025) to 7.81%, marking an increase of 14.95%.
- For Other Income, as of Jun 2025, the value is 0.69 Cr.. The value appears to be declining and may need further review. It has decreased from 0.94 Cr. (Mar 2025) to 0.69 Cr., marking a decrease of 0.25 Cr..
- For Interest, as of Jun 2025, the value is 0.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.11 Cr. (Mar 2025) to 0.12 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 0.27 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.26 Cr. (Mar 2025) to 0.27 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.24 Cr.. The value appears strong and on an upward trend. It has increased from -0.43 Cr. (Mar 2025) to 1.24 Cr., marking an increase of 1.67 Cr..
- For Tax %, as of Jun 2025, the value is 2.42%. The value appears to be increasing, which may not be favorable. It has increased from -37.21% (Mar 2025) to 2.42%, marking an increase of 39.63%.
- For Net Profit, as of Jun 2025, the value is 1.22 Cr.. The value appears strong and on an upward trend. It has increased from -0.27 Cr. (Mar 2025) to 1.22 Cr., marking an increase of 1.49 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.02. The value appears strong and on an upward trend. It has increased from 0.00 (Mar 2025) to 0.02, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:16 am
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Sales | 25.52 | 30.41 | 33.57 | 40.56 |
| Expenses | 25.26 | 30.37 | 33.49 | 39.75 |
| Operating Profit | 0.26 | 0.04 | 0.08 | 0.81 |
| OPM % | 1.02% | 0.13% | 0.24% | 2.00% |
| Other Income | 0.10 | 0.66 | 3.06 | 3.19 |
| Interest | 0.06 | 0.41 | 0.45 | 0.46 |
| Depreciation | 0.02 | 0.04 | 0.81 | 0.93 |
| Profit before tax | 0.28 | 0.25 | 1.88 | 2.61 |
| Tax % | -300.00% | 168.00% | 34.57% | |
| Net Profit | 1.12 | -0.17 | 1.23 | 2.43 |
| EPS in Rs | 0.02 | -0.00 | 0.02 | 0.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2023-2024 | 2024-2025 |
|---|---|---|
| YoY Net Profit Growth (%) | -115.18% | 823.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | 938.71% |
Genpharmasec Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 2 years from 2023-2024 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 1769% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | -22% |
| 3 Years: | -9% |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 2% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:57 am
| Month | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|
| Equity Capital | 27.69 | 55.37 | 55.37 | 55.37 |
| Reserves | -12.36 | 9.02 | 9.79 | 10.31 |
| Borrowings | 3.08 | 3.89 | 5.28 | 11.01 |
| Other Liabilities | 1.46 | 2.84 | 9.45 | 47.31 |
| Total Liabilities | 19.87 | 71.12 | 79.89 | 124.00 |
| Fixed Assets | 0.10 | 0.84 | 7.58 | 42.20 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.95 | 19.32 | 18.84 | 2.05 |
| Other Assets | 18.82 | 50.96 | 53.47 | 79.75 |
| Total Assets | 19.87 | 71.12 | 79.89 | 124.00 |
Below is a detailed analysis of the balance sheet data for Genpharmasec Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 55.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 55.37 Cr..
- For Reserves, as of Sep 2025, the value is 10.31 Cr.. The value appears strong and on an upward trend. It has increased from 9.79 Cr. (Mar 2025) to 10.31 Cr., marking an increase of 0.52 Cr..
- For Borrowings, as of Sep 2025, the value is 11.01 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 5.28 Cr. (Mar 2025) to 11.01 Cr., marking an increase of 5.73 Cr..
- For Other Liabilities, as of Sep 2025, the value is 47.31 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.45 Cr. (Mar 2025) to 47.31 Cr., marking an increase of 37.86 Cr..
- For Total Liabilities, as of Sep 2025, the value is 124.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.89 Cr. (Mar 2025) to 124.00 Cr., marking an increase of 44.11 Cr..
- For Fixed Assets, as of Sep 2025, the value is 42.20 Cr.. The value appears strong and on an upward trend. It has increased from 7.58 Cr. (Mar 2025) to 42.20 Cr., marking an increase of 34.62 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 2.05 Cr.. The value appears to be declining and may need further review. It has decreased from 18.84 Cr. (Mar 2025) to 2.05 Cr., marking a decrease of 16.79 Cr..
- For Other Assets, as of Sep 2025, the value is 79.75 Cr.. The value appears strong and on an upward trend. It has increased from 53.47 Cr. (Mar 2025) to 79.75 Cr., marking an increase of 26.28 Cr..
- For Total Assets, as of Sep 2025, the value is 124.00 Cr.. The value appears strong and on an upward trend. It has increased from 79.89 Cr. (Mar 2025) to 124.00 Cr., marking an increase of 44.11 Cr..
However, the Borrowings (11.01 Cr.) are higher than the Reserves (10.31 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Free Cash Flow | -2.82 | -3.85 | -5.20 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Debtor Days | 81.67 | 109.22 | 147.21 |
| Inventory Days | 151.06 | 133.17 | 101.29 |
| Days Payable | 21.38 | 35.85 | 102.03 |
| Cash Conversion Cycle | 211.34 | 206.54 | 146.47 |
| Working Capital Days | 199.09 | 213.17 | 141.26 |
| ROCE % | 1.52% | 3.32% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.02 | -0.01 |
| Diluted EPS (Rs.) | 0.02 | -0.01 |
| Cash EPS (Rs.) | 0.03 | 0.00 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.18 | 1.17 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.18 | 1.17 |
| Revenue From Operations / Share (Rs.) | 0.60 | 0.54 |
| PBDIT / Share (Rs.) | 0.05 | 0.01 |
| PBIT / Share (Rs.) | 0.04 | 0.01 |
| PBT / Share (Rs.) | 0.03 | 0.00 |
| Net Profit / Share (Rs.) | 0.02 | 0.00 |
| NP After MI And SOA / Share (Rs.) | 0.02 | 0.00 |
| PBDIT Margin (%) | 9.27 | 2.30 |
| PBIT Margin (%) | 6.86 | 2.16 |
| PBT Margin (%) | 5.57 | 0.82 |
| Net Profit Margin (%) | 3.65 | -0.55 |
| NP After MI And SOA Margin (%) | 3.58 | -0.41 |
| Return on Networth / Equity (%) | 1.85 | -0.19 |
| Return on Capital Employeed (%) | 3.30 | 0.96 |
| Return On Assets (%) | 1.51 | -0.17 |
| Long Term Debt / Equity (X) | 0.04 | 0.04 |
| Total Debt / Equity (X) | 0.04 | 0.04 |
| Asset Turnover Ratio (%) | 0.44 | 0.00 |
| Current Ratio (X) | 2.78 | 15.16 |
| Quick Ratio (X) | 1.94 | 11.89 |
| Inventory Turnover Ratio (X) | 3.96 | 0.00 |
| Interest Coverage Ratio (X) | 7.19 | 1.72 |
| Interest Coverage Ratio (Post Tax) (X) | 3.83 | 0.58 |
| Enterprise Value (Cr.) | 102.64 | 108.00 |
| EV / Net Operating Revenue (X) | 3.04 | 3.55 |
| EV / EBITDA (X) | 32.83 | 153.89 |
| MarketCap / Net Operating Revenue (X) | 3.10 | 4.06 |
| Price / BV (X) | 1.61 | 1.92 |
| Price / Net Operating Revenue (X) | 3.10 | 4.06 |
| EarningsYield | 0.01 | 0.00 |
After reviewing the key financial ratios for Genpharmasec Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.02, marking an increase of 0.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.02, marking an increase of 0.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 3. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.18. It has increased from 1.17 (Mar 24) to 1.18, marking an increase of 0.01.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.18. It has increased from 1.17 (Mar 24) to 1.18, marking an increase of 0.01.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.60. It has increased from 0.54 (Mar 24) to 0.60, marking an increase of 0.06.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 2. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.04. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.04, marking an increase of 0.03.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 9.27. This value is below the healthy minimum of 10. It has increased from 2.30 (Mar 24) to 9.27, marking an increase of 6.97.
- For PBIT Margin (%), as of Mar 25, the value is 6.86. This value is below the healthy minimum of 10. It has increased from 2.16 (Mar 24) to 6.86, marking an increase of 4.70.
- For PBT Margin (%), as of Mar 25, the value is 5.57. This value is below the healthy minimum of 10. It has increased from 0.82 (Mar 24) to 5.57, marking an increase of 4.75.
- For Net Profit Margin (%), as of Mar 25, the value is 3.65. This value is below the healthy minimum of 5. It has increased from -0.55 (Mar 24) to 3.65, marking an increase of 4.20.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 8. It has increased from -0.41 (Mar 24) to 3.58, marking an increase of 3.99.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.85. This value is below the healthy minimum of 15. It has increased from -0.19 (Mar 24) to 1.85, marking an increase of 2.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.30. This value is below the healthy minimum of 10. It has increased from 0.96 (Mar 24) to 3.30, marking an increase of 2.34.
- For Return On Assets (%), as of Mar 25, the value is 1.51. This value is below the healthy minimum of 5. It has increased from -0.17 (Mar 24) to 1.51, marking an increase of 1.68.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.04. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.00 (Mar 24) to 0.44, marking an increase of 0.44.
- For Current Ratio (X), as of Mar 25, the value is 2.78. This value is within the healthy range. It has decreased from 15.16 (Mar 24) to 2.78, marking a decrease of 12.38.
- For Quick Ratio (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has decreased from 11.89 (Mar 24) to 1.94, marking a decrease of 9.95.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.96. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 3.96, marking an increase of 3.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.19. This value is within the healthy range. It has increased from 1.72 (Mar 24) to 7.19, marking an increase of 5.47.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.83. This value is within the healthy range. It has increased from 0.58 (Mar 24) to 3.83, marking an increase of 3.25.
- For Enterprise Value (Cr.), as of Mar 25, the value is 102.64. It has decreased from 108.00 (Mar 24) to 102.64, marking a decrease of 5.36.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.04. This value exceeds the healthy maximum of 3. It has decreased from 3.55 (Mar 24) to 3.04, marking a decrease of 0.51.
- For EV / EBITDA (X), as of Mar 25, the value is 32.83. This value exceeds the healthy maximum of 15. It has decreased from 153.89 (Mar 24) to 32.83, marking a decrease of 121.06.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.10. This value exceeds the healthy maximum of 3. It has decreased from 4.06 (Mar 24) to 3.10, marking a decrease of 0.96.
- For Price / BV (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 1.92 (Mar 24) to 1.61, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.10. This value exceeds the healthy maximum of 3. It has decreased from 4.06 (Mar 24) to 3.10, marking a decrease of 0.96.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genpharmasec Ltd:
- Net Profit Margin: 3.65%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.3% (Industry Average ROCE: 15.37%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.85% (Industry Average ROE: 8.86%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.83
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 139 (Industry average Stock P/E: 90.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.04
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.65%
FAQ
What is the intrinsic value of Genpharmasec Ltd?
Genpharmasec Ltd's intrinsic value (as of 07 December 2025) is 2.56 which is 85.51% higher the current market price of 1.38, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 76.4 Cr. market cap, FY2025-2026 high/low of 4.32/1.36, reserves of ₹10.31 Cr, and liabilities of 124.00 Cr.
What is the Market Cap of Genpharmasec Ltd?
The Market Cap of Genpharmasec Ltd is 76.4 Cr..
What is the current Stock Price of Genpharmasec Ltd as on 07 December 2025?
The current stock price of Genpharmasec Ltd as on 07 December 2025 is 1.38.
What is the High / Low of Genpharmasec Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genpharmasec Ltd stocks is 4.32/1.36.
What is the Stock P/E of Genpharmasec Ltd?
The Stock P/E of Genpharmasec Ltd is 139.
What is the Book Value of Genpharmasec Ltd?
The Book Value of Genpharmasec Ltd is 1.19.
What is the Dividend Yield of Genpharmasec Ltd?
The Dividend Yield of Genpharmasec Ltd is 0.00 %.
What is the ROCE of Genpharmasec Ltd?
The ROCE of Genpharmasec Ltd is 3.35 %.
What is the ROE of Genpharmasec Ltd?
The ROE of Genpharmasec Ltd is 1.90 %.
What is the Face Value of Genpharmasec Ltd?
The Face Value of Genpharmasec Ltd is 1.00.